02/23/2026
Why GLP-1 Agonists May Not Be Safe for People with Type 1 Diabetes
GLP-1 receptor agonists — such as semaglutide (Ozempic®, Wegovy®), liraglutide (Victoza®), and tirzepatide (Mounjaro®, Zepbound®) — have dramatically improved treatment options for Type 2 diabetes and obesity. They reduce blood sugar, promote weight loss, and lower cardiovascular risk in ap...